Alnylam Pharmaceuticals, Inc is a company in the U.S. stock market and it is a holding in 124 U.S.-traded ETFs. ALNY has around 7.8M shares in the U.S. ETF market. The largest ETF holder of ALNY is the Vanguard Mid-Cap ETF (VO), with approximately 954.38K shares. Investors may also find of interest that the ETF with the largest allocation to ALNY stock is Direxion mRNA ETF (MSGR), with a portfolio weight of 7.22%. On average, U.S. ETFs allocate 0.60% of ALNY to their portfolios.
Additionally, ALNY is a favorite stock for Vanilla and Active ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with ALNY as a holding is the AGFiQ U.S. Market Neutral Anti-Beta Fund (BTAL), with a return of 16.53%.